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Jaya, MalaysiaA B S T R A C TObjective: To assess the cost-effectiveness of introducing pneumo-
coccal polysaccharide and nontypeable Haemophilus inﬂuenzae protein
D conjugate vaccine (PHiD-CV) in the National Immunization Pro-
gramme of Malaysia. This study compared introducing PHiD-CV
(10 valent vaccine) with current no vaccination, as well as against
the alternative 13-valent pneumococcal conjugate vaccine (PCV13).
Methods: A lifetime Markov cohort model was adapted using
national estimates of disease burden, outcomes of pneumococcal
disease, and treatment costs of disease manifestations including
pneumonia, acute otitis media, septicemia, and meningitis for a
hypothetical birth cohort of 550,000 infants. Clinical information
was obtained by review of medical records from four public hospitals
in Malaysia from the year 2008 to 2009. Inpatient cost from the four
study hospitals was obtained from a diagnostic-related group–based
costing system. Outpatient cost was estimated using clinical path-
ways developed by an expert panel. The perspective assessed was
that of the Ministry of Health, Malaysia. Results: The estimated
disease incidence was 1.2, 3.7, 70, and 6.9 per 100,000 population foree front matter Copyright & 2014, International S
r Inc.
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Lumpur, Malaysiameningitis, bacteremia, pneumonia, and acute otitis media, respec-
tively. The Markov model predicted medical costs of Malaysian ringgit
(RM) 4.86 billion (US $1.51 billion) in the absence of vaccination.
Vaccination with PHiD-CV would be highly cost-effective against no
vaccination at RM30,290 (US $7,407) per quality-adjusted life-year
gained. On comparing PHiD-CV with PCV13, it was found that PHiD-
CV dominates PCV13, with 179 quality-adjusted life-years gained
while saving RM35 million (US $10.87 million). Conclusions: It is
cost-effective to incorporate pneumococcal vaccination in the
National Immunization Programme of Malaysia. Our model suggests
that PHiD-CV would be more cost saving than PCV13 from the
perspective of the Ministry of Health of Malaysia.
Keywords: cost-effectiveness, Malaysia, nontypeable Haemophilus
inﬂuenzae, PHiD-CV, pneumococcal conjugate vaccine, pneumococcal
protein-D conjugate vaccine, Streptococcus pneumoniae, 13-valent
pneumococcal conjugate vaccine.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In Malaysia, an upper-middle–income developing country, vac-
cines have played an important role toward improving health
outcomes of the population over the past ﬁve decades. The
country began vaccinating against important childhood diseases
in the 1960s. Health services afforded mostly by the government
have helped Malaysia to establish a low infant mortality rate of
6.3 per 1000 live births and a maternal mortality rate of 0.3 per
1000 live births [1–3]. Currently, the National Immunization
Programme (NIP) covers many of the main childhood diseases:
diphtheria, pertussis, tetanus, tuberculosis, poliomyelitis, mea-
sles, mumps, rubella, Haemophilus inﬂuenzae b, and hepatitis B [4].Lack of data on pneumococcal disease in Malaysia has been cited
as the main reason for not including the pneumococcal vaccine
in the NIP [5]. One of the reasons in Malaysia, as in many
developing countries, is the lack of ability to conﬁrm the causa-
tive pneumococcal pathogen. Emerging new evidence, however,
points to the beneﬁt of pneumococcal vaccination [6,7].
Globally, Streptococcus pneumoniae (S. pneumoniae) has already
been established as one of the leading causes of vaccine-
preventable diseases and deaths among children younger than
5 years [8]. Many countries have begun to address this issue by
providing pneumococcal vaccination as part of their vaccination
programs, including the United States, Australia, the United
Kingdom, Norway, Japan, as well as Colombia [9–14]. Severalociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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vaccination, including the 7-valent pneumococcal conjugate
vaccine (PCV7), pneumococcal polysaccharide and nontypeable
Haemophilus inﬂuenzae protein D conjugate vaccine (PHiD-CV), and
the 13-valent pneumococcal conjugate vaccine (PCV13). The
result of cost-effectiveness studies between PHiD-CV and PCV13
in different countries varies depending on the outcome of
interest and country-speciﬁc input data parameters. An earlier
study showed that the PCV7 vaccine would be cost-effective for
Malaysia as compared with no vaccination, with an incremental
cost-effectiveness ratio (ICER) of Malaysian ringgit (RM) 35,196 (US
$10,261) per life-year gained based on 2007 prices, which would
be well below the World Health Organization threshold for
Malaysia, which was RM71,761 (US $20,922) [7]. The cost-
effectiveness of the other available pneumococcal vaccines,
however, has not been evaluated locally.
The objective of this study was to assess the cost-
effectiveness of introducing PHiD-CV in the NIP of Malaysia. ThisFig. 1 –Markov cohort model. The cohort model is Markov based,
death. The transition from “no” disease to “sequelae” or “death”
pneumonia has only short-term sequelae whereas meningitis c
include NTHi meningitis and NTHi bacteremia, respectively; and
impact calculation. AOM, acute otitis media; GP, general practiti
Haemophilus inﬂuenzae.study compares introducing PHiD-CV (10 valent vaccine) with
current no vaccination, as well as against the alternative 13
valent vaccine (PCV13).Methods
Using Malaysian epidemiological data, clinical outcome, and cost
inputs, we adapted a Markov cohort model developed by Knerer
et al. [15]. The model was static, deterministic, and compartmen-
talized by age. The health states built into the model are shown
in Fig. 1. The model simulated the health and cost effects of
vaccination in a birth cohort of 550,000 infants followed in
monthly cycles up to 100 years. A monthly cycle duration was
applied to simulate the nature of infections whereby the cohort
could be exposed to repeated infections over a relatively short
period of time. Half-cycle correction was not applied because of
the short cycle duration. Within the model, three disease typeswith three exclusive health states: no disease, sequelae, and
is calculated on the basis of this decision tree. In the model,
an lead to long-term sequelae; meningitis and bacteremia
nonconsulting AOM are accounted for in the quality-of-life
oner; PCP, primary care physician; NTHi, nontypeable
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(meningitis and bacteremia), community-acquired pneumonia,
and acute otitis media (AOM). The model also incorporated
pneumonia caused by S. pneumoniae or nontypeable Haemophilus
inﬂuenzae (NTHi). The analysis was performed from the payer
perspective (Ministry of Health, Malaysia).
This study was approved by the ethics committees of the
Universiti Kebangsaan Malaysia (UKM) (FF-027-2010) and the
Ministry of Health, Malaysia (NMRR-09-1087-4866).
Epidemiology Parameters
Disease incidence was estimated on the basis of a review of
medical records from January 1, 2008, to December 1, 2009, from
four tertiary public hospitals from various regions of Malaysia,
namely, UKM Medical Centre, Hospital Kuala Lumpur, Hospital
Alor Setar, and Hospital Queen Elizabeth, Kota Kinabalu. The four
study hospitals were selected to represent various regions of
Malaysia.
Inpatient discharge records were used to identify cases of
pneumococcal meningitis, bacteremia, pneumonia, and AOM.
Cases were primarily identiﬁed by using International Statistical
Classiﬁcation of Diseases,10th Revision codes. For the purpose of this
study, International Statistical Classiﬁcation of Diseases,10th Revision
pneumococcal disease codes include the following: pneumococ-
cal meningitis (G00.1), bacterial meningitis unspeciﬁed (G00.9),
pneumococcal septicemia (A40.3), streptococcal septicemia
unspeciﬁed (A40.9), pneumonia due to S. pneumoniae (J13), other
unspeciﬁed pneumonia (J15.9, J18, and J18.9), and otitis media
(H65, H66, and H66.9). Additional patient-level data for S. pneumo-
niae culture and sensitivity result were reviewed from laboratory
records. All patient-level data were anonymized before analysis.
Estimation of Incident Rates
The estimation of incidence rates was based on the number of
cases, stratiﬁed by age, identiﬁed at the four study hospitals,
extrapolated for the catchment population of the respective
hospitals. Based on discussions with hospital administrators
and clinical experts from the study hospitals, the catchment
population for each hospital was assumed to be the entire
population within the hospitals’ district plus 30% of the state
population. The data for district populations, based on year 2010,
were obtained from the Department of Statistics, Malaysia. The
national incidence rate by age group was adjusted to the year of
analysis (2010) and was estimated as the average disease rate
across the catchment population of four hospitals. The rates of
pneumonia and AOM treated in the outpatient setting in the four
study hospitals were assumed to be similar to the ratio of
inpatient to outpatient cases in another regional study [16].
Vaccine Efﬁcacy
The efﬁcacy of PHiD-CV and PCV13 vaccine against invasive
forms of pneumococcal disease was determined for all relevant
S. pneumoniae serotypes on the basis of data from clinical trials
and past studies [17,18]. Similar to other studies, we incorporated
the effect of vaccination on disease caused by NTHi in AOM
[12,14,15]. The efﬁcacy data of PHiD-CV and PCV13 against
pneumonia, IPD due to NTHi, and AOM were obtained from past
studies [19–21] (Table 1). The model took into account serotype
distribution in Malaysia following the results of a local study [6]
(see Appendix 1 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.vhri.2014.04.008. The effects of serotype and patho-
gen replacement were also included by assuming reductions in
efﬁcacy (negative efﬁcacy) toward serotypes of S. pneumoniae and
NTHi that were not protected by the vaccines (Table 1).Vaccination was assumed to be administered in a 3 þ 1 dosing
regimen for both PHiD-CV and PCV13 given at 2, 3, 4, and 13
months, respectively. To reduce model complexity, all infants
were assumed to have received the complete 3 þ 1 course of
vaccination. The vaccine coverage was assumed to be 95%,
consistent with previous implementation of vaccine programs
in Malaysia [4]. Similar to Knerer et al.’s study [15], the vaccine
efﬁcacy rate is assumed to achieve a full efﬁcacy at the last dose
at 13 months, and maintain full efﬁcacy until age 3 years, with a
ﬁxed linear waning period applied until the age of 10 years. The
effect of herd or indirect protection effects in the unvaccinated
population was incorporated into the model. Following Knerer
et al., we assumed that vaccination with PHiD-CV and PCV13 has
a net indirect effect resulting in a 15.4% reduction in IPD in those
younger than 5 years and 29% in those aged 5 years or older.Quality of Life
Lifetime utility weights of quality of life (QOL) and disease types
were applied to the model to calculate quality-adjusted life-years
(QALYs) gained. The model incorporated disutility resulting from
the long-term sequelae of IPD as well as temporary reductions in
QOL arising from each episode of the disease of interest, with
greater reductions in QOL due to more severe disease. We used an
approach similar to that of Knerer et al. and applied utility weights
from other populations in our analysis because these data were not
available from the local setting. [22–25] (Table 1). Average lifetime
QOL was assumed to be 0.83 out of 1.0 (where 1.0 was perfect
health) in the analysis data from the United Kingdom [26].Estimation of Costs
The study incorporates costs of direct medical resources incurred
by the Ministry of Health for the treatment of an episode of
pneumococcal disease. Costs incurred by patients, such as out-
of-pocket expenses, were excluded in the study.
Outpatient treatment costs included the cost of physician
consultation, drugs, and diagnostic test resources used during
preadmission and postdischarge visits to the outpatient depart-
ment. Resource utilization during visits was estimated from
clinical pathways developed with the help of an expert panel
group and varied depending on the disease type. Costs of out-
patient treatments that were not linked to hospital admission
were excluded.
The cost of each episode of hospitalization was calculated as
the cost per day of hospitalization in each of the four study
hospitals multiplied by the duration of stay. Hospitalization cost
included the cost of physician consultation and other human
resources, drugs and supplies, equipment, tests, surgeries, and
utilities. Costs varied by the type of admission based on their
diagnosis using a diagnosis-related group system developed by
the United Nations University International and the National
University of Malaysia. The cost of each diagnosis-related group
at the four study hospitals was estimated by top-down costing
using the Clinical Costing Modelling Software (Version 1.0), which
distributes costs into three different cost center levels according
to allocation factors (e.g., ﬂoor area, staff counts, and patient
counts). [7,27]. The following conventions were used for imputing
capital and recurrent costs incurred during hospitalization.Capital cost
The life span of equipment and vehicles was assumed at 5 years,
with an annual depreciation of 5%. Only areas and vehicles used
within the activity scope of this study were considered. Building
cost was not included.
Table 1 – Vaccine efﬁcacy by disease manifestation, quality-of-life utility weights, and cost data inputs (RM).
Vaccine efﬁcacy
Disease manifestation PHiD-CV (%) PCV13 (%) Source
Vaccine efﬁcacy
Efﬁcacy against IPD (by pneumococcal serotype)
1 94.7 94.7 Assumed from average efﬁcacy reported by Whitney et al. [18]
3 0 0 Andrews et al. [17]
4 93 93 Whitney et al. [18]
5 94.7 94.7 Assumed from average efﬁcacy reported by Whitney et al. [18]
6A 76 94.7 Whitney et al. [18]
6B 94 94 Whitney et al. [18]
7F 94.7 94.7 Assumed from average efﬁcacy reported by Whitney et al. [18]
9V 99.9 99.9 Whitney et al. [18]
14 94 94 Whitney et al. [18]
18C 97 97 Whitney et al. [18]
19A 26 94.7 Whitney et al. [18]
19F 87 87 Whitney et al. [18]
23F 98 98 Whitney et al. [18]
Efﬁcacy against all-cause pneumonia
Reduction in hospitalization 23.4 23.4 Tregnaghi et al. [19]
Reduction in GP visits 7.3 7.3 Tregnaghi et al. [19]
Efﬁcacy against IPD due to NTHi 35.0 0 Tregnaghi et al. [19]
Efﬁcacy against AOM
Efﬁcacy against AOM due to S. pneumoniae vaccine serotypes 57.6 57.6 Prymula et al. [20]
Efﬁcacy against AOM due to S. pneumoniae nonvaccine serotypes 33 33 Eskola et al. [21]
Efﬁcacy against AOM due to NTHi 35.6 11 PHiD-CV: Prymula et al. [20]; PCV13: Eskola et al. [21]
Net indirect reduction in IPD (herd protection)
r5 y 15.4 15.4 Knerer et al. [15]
45 y 29 29 Knerer et al. [15]
QOL utility weights
Resource Utility weight Remarks/source
Normative lifetime QOL 0.83 English Department of Health [26]
Short-term disutility per disease episode
Meningitis (inpatient) 0.023 Bennett et al. [22]
Bacteremia (inpatient) 0.008 Bennett et al. [22]
Pneumonia (inpatient) 0.008 Assumed to be equal to inpatient bacteremia
Pneumonia (outpatient) 0.006 Assumed equal to local bacteremic infection reported by Bennett et al. [22]
AOM (outpatient) 0.005 Melegaro and Edmunds [23]
AOM (hospitalized myringotomy) 0.005 Assumed to be equal to outpatient AOM
Long-term disutility from disease sequelae
Meningitis 0.27 Morrow et al. [24]
Bacteremia 0.27 Morrow et al. [24]
AOM 0.09 Oostenbrink et al. [25]
Cost data inputs (RM)
Resource Cost Remarks/source
Vaccine –
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Recurrent costs included the cost of labor and supplies. Labor
costs included salaries, bonuses, and allowances to health care
personnel. Cost of supplies was calculated as the total cost of all
purchases of medication and nonmedication items. Utility costs
due to water, electricity supply, telephone, and waste mainte-
nance were calculated for each activity within the scope of
the study.
All costs were calculated in Malaysian ringgit (RM) for the year
2010 (US $1 ¼ RM3.22) [28].Cost-Effectiveness Analysis
The model was used to estimate the effect of (1) PHiD-CV
compared with no vaccination and (2) PHID-CV compared with
PCV13 in a birth cohort of 550,000 infants over a 100-year time
horizon. Other inputs and assumptions are described in Table 1
and in Appendices 2, 3, 4, and 5 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2014.04.008.
Cost-effectiveness was expressed as cost per life-year gained
(LYG) and cost per QALY gained. LYG was determined by taking
into consideration the average life expectancy minus the age of
death due to disease (LYG ¼ average life expectancy – age of
expected death). QALY gained was calculated in a similar manner
using QALY instead of life-years. All costs and outcomes were
discounted at 5% per annum in the base-case analysis. On the
basis of the recommendation by the World Health Organization,
we assume a cost-effectiveness threshold for health interven-
tions of less than three times the per-capita gross domestic
product (GDP) [29].
One-way sensitivity analyses were carried out for the base-
case scenario of PHiD-CV 3 þ 1 vaccination program versus no
vaccination and PHiD-CV 3 þ 1 vaccination program versus
PCV13 3 þ 1 vaccination program. The sensitivity analysis was
performed by varying variables by 20% from their base-case
value. The results of sensitivity analyses were shown as tornado
diagrams for the 10 variables with the highest differences.Results
Burden of Disease
The incidence rate was 1.2 per 100,000 population for meningitis,
3.7 per 100,000 for bacteremia, 70 per 100,000 for pneumonia, and
6.9 per 100,000 for AOM. Age-speciﬁc incidence rates are provided
in Appendices 3, 4, and 5 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.vhri.2014.04.008. This is translated into
2,331,202 pneumococcal cases (98% outpatient, 2% inpatient)
annually. The total cost of pneumococcal disease without vacci-
nation is estimated to be RM1402 million (US $435.6 million); the
estimated cost of meningitis is RM3.7 million (US $1.2 million);
bacteremia, RM28 million (US $8.6 million); pneumonia, RM704
million (US $218.5 million); and AOM, RM667 million (US $207.3
million) (Table 2).
Our analysis showed that vaccination reduces deaths and
hospitalizations due to meningitis, bacteremia, pneumonia, and
AOM. Vaccinating with PHiD-CV or PCV13 produces a similar
reduction in the rates of meningitis, bacteremia, and pneumonia.
PHiD-CV vaccination, however, results in much fewer cases of
hospitalized myringotomy and outpatient AOM than does PCV13
(Table 3). The modeling analysis shows that PHiD-CV will save
RM35 million (US $10.87 million) and result in 179 more QALYs
gained as compared with PCV13 (Table 4).
Table 2 – Costs of pneumococcal disease.
Disease
Cases per year
(child)
Cases per year
(adult)
Total cases per
year
Cost (RM)
adult
Cost (RM)
child
Cost (RM)
all
Meningitis 2,809 3,737,584
Inpatient 155 236 391 932,192 1,177,549 2,109,741
Outpatient 1,237 1,181 2,418 1,019,581 608,262 1,627,843
Septicemia 17,775 27,734,570
Inpatient 166 885 1,051 733,162 2,034,129 2,767,291
Outpatient 1,692 15,032 16,724 1,743,178 23,224,101 24,967,279
Pneumonia 1,251,424 703,689,018
Inpatient 6,570 16,267 22,837 20,865,658 50,101,036 70,966,694
Outpatient 269,311 959,276 1,228,587 138,695,211 494,027,113 632,722,324
AOM 1,059,193 667,447,841
Inpatient 19,528 5,811 25,339 43,430,272 2,992,665 46,422,937
Outpatient 860,098 173,756 1,033,854 531,540,564 89,484,340 621,024,904
Total 1,158,757 1,172,444 2,331,201 738,959,818 663,649,195 1,402,609,013
Note. US $1 ¼ RM3.22.
AOM, acute otitis media; RM, Malaysian ringgit.
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Based on the estimated incidence, pneumococcal disease would
incur a total cost of RM1,403 million (US $435.6 million) per year
to the Malaysian health system, as shown in Table 2. The cost of
vaccination, either with PHiD-CV or with PCV13, would incur a
cost of RM158.76 million (US $49.3 million) for the study birth
cohort, assuming equal costs of RM80 (US $24.84) per dose for
PCV13 and PHiD-CV vaccines, respectively. In the absence of
vaccination, the health system would incur an undiscounted cost
of RM4,858 million (US $1,509 million) for the cohort of 550,000
over the course of their lifetime. With vaccination, direct medical
care costs would be reduced by RM93.5 million (US $29 million)
for PHiD-CV and by RM55.1 million (US $17.1 million) for
PCV13. The majority of the cost saving difference between
PHiD-CV and PCV13 is due to the greater reduction in cases of
AOM (Table 3).
In terms of cost-effectiveness, PHiD-CV vaccination has a dis-
counted ICER of RM34,328 (US $10,661) per LYG and RM30,290 (US
$9,407) per QALY gained compared with a no-vaccination strategy.
When comparing against PCV13, PHiD-CV would save discounted
costs of RM35 million (US $10.9 million), with 98 fewer discounted
life-years, with a discounted ICER of RM359,662 (US $111,696). InTable 3 – Model outcomes results (cases) and model cost
Cost/outcome Variables
Outcome (cases) Meningitis Deaths
Hospitalizati
Bacteremia Deaths
Hospitalizati
Pneumonia Deaths
Hospitalizati
Outpatient c
Acute otitis media Hospitalized
Outpatient c
Undiscounted costs (RM million) Vaccine
Medical care costs
Total costs
Note. US $1 ¼ RM3.22.
PCV13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, pneumococ
conjugate vaccine; RM, Malaysian ringgit.contrast, PHiD-CV would gain 179 discounted QALYs compared
with PCV13. Therefore, PHiD-CV dominates over PCV13, with an
ICER of RM196,618 (US $61,061) per QALY gained (Table 4).
Because Malaysia’s GDP in 2010 was RM28,142 (US $8,740) per
capita, the base-case result shows that the PHiD-CV vaccine would
be cost-effective for Malaysia on the basis of the World Health
Organization threshold of less than three times the per-capita GDP,
RM84,426 (US $26,219) per LYG or QALY gained in 2010 [29].Sensitivity Analyses
Fig. 2 presents the one-way sensitivity analysis of the effect of the
10 most inﬂuential variables on a cost-effectiveness plane gen-
erated by comparing the PHiD-CV 3 þ 1 vaccination program with
no vaccination. The tornado diagram indicates that the cost-
effectiveness is robust because none of the factors caused the
ICER of PHiD-CV to exceed the per-capita GDP threshold of
RM84,426 (US $26,219) per QALY.
Fig. 3 presents similar sensitivity analysis comparing PHiD-CV
3 þ 1 and PCV13 3 þ 1 vaccination. The tornado diagram shows
that varying the input variables does not alter the cost-saving
conclusion of PHiD-CV 3 þ 1 vaccination compared with PCV13.s results (RM million).
No vaccination PHiD-CV PCV13
187 161 158
on 595 549 543
302 295 294
on 2,113 2,064 2,058
50,443 50,373 50,373
on 196,871 194,011 194,012
are 6,785,769 6,769,532 6,769,397
myringotomy 27,251 20,294 23,849
are 1,200,793 1,094,123 1,148,187
0 158.76 158.76
4,858.30 4,764.80 4,803.22
4,858.30 4,923.56 4,961,99
cal polysaccharide and nontypeable Haemophilus inﬂuenzae protein D
F
e
i
c
v
Table 4 – Cost-effectiveness (3% discount rate).
Cost/outcome No
vaccination
PHiD-CV PCV13 ICER, PHiD-CV no
vaccine
ICER, PHiD-CV 
PCV13
Total costs (RM million) 1,823.27 1,894,49 1,929.61 74.36 35
LYs gained (discounted) 16,154,237 16,156,312 16,156,409 2,351 98
QALY gained
(discounted)
13,392,681 13,395,033 13,394,854 2,075 179
ICER (LYs gained) 34,328 359,662
ICER (QALY gained) 30,290 196,618*
Note. US $1 ¼ RM3.22.
ICER, incremental cost-effectiveness ratio; LY, life-year; PCV13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, pneumococcal
polysaccharide and nontypeable Haemophilus inﬂuenzae protein D conjugate vaccine; QALY, quality-adjusted life-year.
* PHiD-CV dominates PCV13 with cost savings and more QALYs.
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The results of our study indicate that PHiD-CV is a cost-effective
strategy in Malaysia as compared with no vaccination. Similar to
previous studies [9,12,14,15], when comparing PHiD-CV with
PCV13, PHiD-CV is advantageous and dominant over PCV13 in
terms of QALYs. The QALYs gained are due to its greater effect on
the number of AOM cases via its efﬁcacy against NTHi compared
with PCV13. In terms of LYG, however, PHiD-CV and PCV13 are
virtually identical due to the comparable efﬁcacy of both vaccines
on IPD and pneumonia. Although not part of the objectives of this
study, a separate analysis of PCV13 versus no vaccination indicates
that PCV13 vaccination would be cost-effective over no vaccination.
The model used in this study is similar to the one used in a
previously published study [15] and it uses local epidemiological
inputs derived from a large pool of patient data from four study
hospitals as well as local data on serotype coverage.ig. 2 – Tornado diagram of one-way sensitivity analysis of the e
ffectiveness results of PHiD-CV vs. no vaccination. Note: Red bars
ndicate the effect of low sensitivity values on the ICER per QALY
ost-effectiveness ratio; PHiD-CV, pneumococcal polysaccharide a
accine; QALY, quality-adjusted life-year.In the context of the Malaysian health system, the four
hospitals in this study are referral centers for the government-
funded public health system in their respective catchment areas.
They are more likely to treat serious cases because such patients
would be referred to their care from other public sector facilities
within their catchment area. Services in public facilities are fully
funded by the government, with a nominal fee charged for most
services. Alongside the public system, there also exists in Malaysia
a large private health care industry that includes private hospitals
that charge market rates for services. Because of their higher cost,
private hospitals are concentrated in major cities and treat only
18% of all inpatient cases [30].
The model used in this study uses the latest efﬁcacy data from
multicountry and pivotal clinical trials conducted in populations
from Europe and North and South America [17–21]. The model also
follows a birth cohort through the course of its lifetime. Another
positive aspect of the model is that it assumes an equal cost for
two vaccines, which allows our study to place greater focus onffect of the 10 most inﬂuential variables on the cost-
indicate the effect of high sensitivity values, and blue bars
gained of PHiD-CV vs. no vaccination. ICER, incremental
nd nontypeable Haemophilus inﬂuenzae protein D conjugate
Fig. 3 – Tornado diagram of one-way sensitivity analysis of the effect of the 10 most inﬂuential variables on the cost-
effectiveness results of PHiD-CV vs. PCV13. Note: Red bars indicate the effect of high sensitivity values, and blue bars indicate
the effect of low sensitivity values on the ICER per QALY gained of PHiD-CV vs. no vaccination. ICER, incremental cost-
effectiveness ratio; PCV13, 13-valent pneumococcal cunjugate vaccine; PHiD-CV, pneumococcal polysaccharide and
nontypeable Haemophilus inﬂuenzae protein D conjugate vaccine; QALY, quality-adjusted life-year.
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be subject to adjustment based on price negotiations.
Our study has recognized limitations. First, within the scope
of the study, we conducted the analyses for PHiD-CV versus no
vaccine and PHiD-CV versus PCV13 only. We did not include the
other option of PCV7 in the study. An earlier study [7] had
estimated that vaccination with PCV7 of the Malaysian birth
cohort would avoid 408 deaths over 10 years compared with no
vaccination. PCV7 was estimated to be cost-effective in the
Malaysian setting, with an ICER of RM35,196 (US $10,261) per
LYG. In comparison, PHiD-CV in the current study has a similar
ICER of RM34,328 (US $10,661) per LYG compared with no
vaccination, although it should be noted that the two studies
were not exactly alike methodologically Because PCV7 is already
upgraded to a 13 valent vaccine (PCV13), we did not consider a
comparison against PCV7 necessary.
Second, our estimation of disease incidence may have
underestimated the number of pneumonia cases because data
were collected on the basis of four academic and government
hospitals. We may have missed patients who presented with
symptoms to other health facilities within or catchment areas
around the four study centers, whether private or government.
Regarding private hospitals, the numbers of patients presenting
to these centers are likely to be small. There are also govern-
ment facilities within or near the catchment areas that could
dilute the patient population presenting to our sites. This is
especially true for the two hospitals in the nation’s capital, UKM
Medical Centre and Hospital Kuala Lumpur. The overall impact
of this is that the incidence of disease may have been under-
estimated, which is not ideal. However, if true disease incidence
was actually higher, then the cost-effectiveness of the vaccine
would be better than the results we have provided. Hence,despite this limitation, we believe that the results of our study
still hold.
The analysis also did not include the cost of vaccine admin-
istration. In the analysis comparing PHiD-CV with PCV13, the
exclusion has no effect on the ICER because both vaccines would
have the same dosing regimen and would incur equal admin-
istration cost. For the comparison between PHiD-CV and no
vaccination, the addition of administration cost would increase
the total cost of the PHiD-CV strategy and consequently increase
the ICER of PHiD-CV compared with no vaccination. Administra-
tion costs, however, would be relatively low because Malaysia has
an existing NIP and vaccination with PHiD-CV would be incorpo-
rated into the program.
We acknowledge that several data inputs into the model
were obtained from studies on non-Malaysian populations
because of the absence of published local data. The effect of
PHiD-CV was driven by its impact on AOM, but local epide-
miological data were not available for Malaysia. Hence, data
from a study within the region were used in the model [16].
Meanwhile, expert panel advice for clinical pathways was used
to estimate the number of outpatient visits and determine the
cost. Although it would have been preferable to incorporate
herd effects and utility weights of disease manifestations from
the local population, these were unavailable and inputs were
drawn from studies from Canada, the United States, and the
United Kingdom [15,22–24]. External data were used in the
absence of local data because the authors felt that these
factors were important and could not be reasonably ignored
in the present analysis. Sensitivity analysis indicated that
these factors did not alter the conclusions from the base-
case result of the study that PCV13 was dominated by PHiD-
CV.
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PCV13 with substantial ﬁnancial savings and higher health
gains (measured in QALYs), which is largely due to a larger
reduction in AOM. Similar to ﬁndings in Australia [9], the choice
would also depend on the burden of AOM, data for which are
not currently available for Malaysia. As mentioned, this study
used data from a regional study [16] as model inputs because of
the scarcity of Malaysian epidemiological estimate of AOM.
When life-years are used as the outcome measure, PCV13 is
marginally more effective in reducing mortality compared with
PHiD-CV, but the 98 life-years difference is based on the entire
birth cohort of 550,000 and the additional life-years each come
at a cost of RM359,662 (US $111,696). It should also be noted that
the model simulated the health and cost effects for a single
birth cohort of 550,000 infants and not for all subsequent
cohorts as would be the case if pneumococcal vaccine were to
be added to the NIP. Given the paucity of local data as discussed
above, these ﬁndings should be interpreted carefully within the
context of a modeling-based analysis and may be revised as
more local evidence becomes available. To strengthen the
ﬁndings of this study, further research should be conducted to
obtain the local data inputs related to some aspects of the
model such as herd effects, QOL impact of pneumonia and
related conditions, and medical utilization in the outpatient
setting.Conclusions
Our results show that PHiD-CV has an ICER that dominates over
that of PCV13 at an incremental cost of RM196,618 (US $61,061)
per QALY, as greater QALYs gained with PHiD-CV come at a lower
cost. These cost savings from PHiD-CV are driven by a reduction
in manifestations and complications of AOM, which result in a
much greater beneﬁt over the course of a lifetime of the
simulated vaccinated cohort. When compared using LYG, vacci-
nation with PCV13 or PHiD-CV has virtually equal gains in LYG
but lower cost with PHiD-CV vaccination at an ICER of RM359,662
(US $111,696) per LYG. Therefore, on the basis of the study results,
we conclude that the inclusion of PHiD-CV in the NIP would be
cost-effective for Malaysia.Acknowledgments
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